Prime Medicine, Inc. (PRME) stock
PRMENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$4.27+0.38 (+9.77%)
Close on Nov 13, 2026Market cap $774.48MP/E –Yield –
Prime Medicine ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Prime Medicine's ebitda for the twelve months ending Sep 30, 2026 was -$175.20M. For fiscal 2025 it was -$201.03M. The highest annual figure on record is -$889.00K in fiscal 2020.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$201.03M | – |
| FY2024 | Dec 31, 2024 | -$196.34M | – |
| FY2023 | Dec 31, 2023 | -$200.14M | – |
| FY2022 | Dec 31, 2022 | -$114.32M | – |
| FY2021 | Dec 31, 2021 | -$83.91M | – |
| FY2020 | Dec 31, 2020 | -$889.00K | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$38.17M | – |
| Q2 FY2026 | Jun 30, 2026 | -$41.50M | – |
| Q1 FY2026 | Mar 31, 2026 | -$48.80M | – |
| Q4 FY2025 | Dec 31, 2025 | -$46.73M | – |
| Q3 FY2025 | Sep 30, 2025 | -$52.09M | – |
| Q2 FY2025 | Jun 30, 2025 | -$51.51M | – |
| Q1 FY2025 | Mar 31, 2025 | -$50.69M | – |
| Q4 FY2024 | Dec 31, 2024 | -$42.51M | – |
| Q3 FY2024 | Sep 30, 2024 | -$52.67M | – |
| Q2 FY2024 | Jun 30, 2024 | -$54.13M | – |
| Q1 FY2024 | Mar 31, 2024 | -$47.03M | – |
| Q4 FY2023 | Dec 31, 2023 | -$66.80M | – |
| Q3 FY2023 | Sep 30, 2023 | -$50.22M | – |
| Q2 FY2023 | Jun 30, 2023 | -$44.14M | – |
| Q1 FY2023 | Mar 31, 2023 | -$38.98M | – |
| Q4 FY2022 | Dec 31, 2022 | -$37.82M | – |
| Q3 FY2022 | Sep 30, 2022 | -$31.02M | – |
| Q2 FY2022 | Jun 30, 2022 | -$25.88M | – |
| Q1 FY2022 | Mar 31, 2022 | -$19.61M | – |
| Q4 FY2021 | Dec 31, 2021 | -$59.85M | – |
| Q3 FY2021 | Sep 30, 2021 | -$10.23M | – |
See a number that looks wrong?